PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in
treating young patients with recurrent or refractory primary central nervous system tumors.